-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$84.4492.87% Upside
Recent Analyst Forecasts and Stock Ratings
Tandem Diabetes Care, Inc. Frequently Asked Questions
-
What analysts cover Tandem Diabetes Care, Inc.?
Tandem Diabetes Care, Inc. has been rated by research analysts at Canaccord Genuity, Barclays, Piper Sandler, Robert W. Baird, Oppenheimer, Stifel Nicolaus in the past 90 days.